← Volver a la portada
Estados Unidos · Plataformas y datos · Yahoo Finance

Novartis Says AI Is Speeding Drug Discovery and Trials, but Clinical Payoff Remains Unproven

Publicado por Yahoo Finance · Estados Unidos hace 3 d
Novartis logo
Novartis logo · Yahoo Finance

Resumen detallado

Novartis (NYSE:NVS) is applying artificial intelligence across drug research and clinical development, with executives reporting faster trial enrollment and drug candidate…

Novartis (NYSE:NVS) is applying artificial intelligence across drug research and clinical development, with executives reporting faster trial enrollment and drug candidate selection while cautioning that evidence of improved clinical success will take longer to emerge.

At an investor event, company leaders described how AI is being used to identify drug targets, design molecules, plan clinical trials and analyze safety data. They also stressed that researchers must validate AI-generated findings in the laboratory and, ultimately, in clinical trials.

→ The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch

Max Lawson, head of AI and process innovation at Novartis, said AI-enabled site selection accelerated enrollment by six months in the company's V1P effort. He also said 90% of the content in clinical study reports is now AI-assisted, reducing authoring and review time by 25%.

Lawson said the company's Intelligent Decision System can run thousands of simulations of a potential study in minutes. The simulations were 50% more accurate at predicting enrollment timelines than the prior planning process, he said.

Fiona Marshall, president of biomedical research, said the average time from starting a research program to selecting a drug candidate has fallen from three to four years to less than 2.5 years. Much of that gain came from AI-assisted generative chemistry, she said. Some programs driven primarily by AI have reached a one-year cycle time, though the company is still collecting comparative data.

Marshall said eight or nine molecules developed through generative chemistry and predictive safety processes are undergoing dose-range-finding toxicology work. Data on whether the approach reduces safety-related attrition could be available within a few years, she said.

→ NVIDIA's Turbulence Could Have Ripple Effects Across Quantum Computing

Christian Diehl, Novartis' chief data and digital officer, said the company has generated more than 150 petabytes of…

Inicio del artículo, extracto de Yahoo Finance. Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en Yahoo Finance Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finance.yahoo.com)

También te puede interesar